Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
M.D. Anderson Cancer Center |
---|---|
Information provided by: | M.D. Anderson Cancer Center |
ClinicalTrials.gov Identifier: | NCT00038831 |
Primary Objective:
1. To determine the safety and maximum tolerated dose of Mylotarg as part of a reduced-intensity preparative regimen patients undergoing related, mismatched-related or matched unrelated donor transplantation.
Secondary Objectives:
Condition | Intervention | Phase |
---|---|---|
Acute Myelogenous Leukemia Myelodysplastic Syndrome Chronic Lymphocytic Leukemia |
Drug: Mylotarg |
Phase I Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Phase I/II Evaluation of Safety and Activity of Mylotarg Plus Melphalan and Fludarabine as Preparative Therapy for Older or Medically Infirm Patients Undergoing Allogeneic Bone Marrow and Peripheral Blood Stem Cell Transplantation |
Estimated Enrollment: | 44 |
Study Start Date: | May 2001 |
Estimated Study Completion Date: | March 2005 |
Allogeneic bone marrow transplantation is an effective first line and salvage therapy in-patients with AML, CML or MDS. In the past, allogeneic transplantation has been limited to younger patients due to the increased risk of regimen-related toxicity and graft-versus-host disease (GVHD). In order to expand the use of alloBMT to older patients, researchers at MD Anderson Cancer Center have pioneered the use of nonmyeloablative preparative therapy for allogeneic transplantation. Nonmyeloablative therapy utilizes low-dose chemotherapy in order to decrease regimen-related toxicity. The low-dose chemotherapy induces host immunosuppression, spares toxicity, and allows engraftment of donor stem cells. The goal of this therapy is to exploit the anti-tumor effects of donor immune cells.
One shortcoming of nonmyeloablative transplantation is an increased risk of disease relapse, especially in patients with high-risk disease. This includes patients with relapse or refractory AML, advanced MDS and advanced CML. Mylotarg is a novel immunotoxin directed against the CD33 antigen found on most AML, CML and MDS clones. Mylotarg has been shown to have significant anti-leukemia activity with little toxicity. The goal of this Phase I/II protocol is to evaluate the safety and efficacy of adding escalating doses of Mylotarg to Fludarabine and Melphalan in patients with CML, MDS or acute myelogenous leukemia undergoing related, mismatch-related or matched unrelated donor allogeneic transplantation. The hypothesis is that Mylotarg will provide potent anti-leukemic effects without additional toxicity. Mylotarg, Melphalan, and Fludarabine have non-overlapping toxicities. A more potent anti-leukemic response may increase the complete remission rates and induce a state of minimal residual disease (MRD). Therefore, the GVL effect will have a better chance for success.
Ages Eligible for Study: | 55 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Patients with the following disease categories will be eligible:
Exclusion Criteria:
United States, Texas | |
MD Anderson Cancer Center | |
Houston, Texas, United States, 77030 |
Principal Investigator: | Marcos De Lima, MD | U.T. M.D. Anderson Cancer Center |
Study ID Numbers: | ID01-010 |
Study First Received: | June 5, 2002 |
Last Updated: | July 6, 2007 |
ClinicalTrials.gov Identifier: | NCT00038831 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Acute Myelogenous leukemia Myelodysplastic Syndrome Chronic Lymphocytic Leukemia Mylotarg |
Melphalan Leukemia, Lymphoid Immunoproliferative Disorders Precancerous Conditions Hematologic Diseases Myelodysplastic Syndromes Fludarabine monophosphate Leukemia, Myeloid Gemtuzumab Leukemia, Myeloid, Acute Leukemia |
Lymphatic Diseases Chronic Lymphocytic Leukemia Acute Myelocytic Leukemia Preleukemia Acute Myeloid Leukemia, Adult Leukemia, Lymphocytic, Chronic, B-Cell Fludarabine Leukemia, B-cell, Chronic Leukemia, B-Cell Lymphoproliferative Disorders Bone Marrow Diseases |
Leukemia, Lymphoid Precancerous Conditions Antineoplastic Agents Leukemia, Myeloid, Acute Leukemia Preleukemia Pathologic Processes Leukemia, Lymphocytic, Chronic, B-Cell Syndrome Therapeutic Uses Neoplasms by Histologic Type Immunoproliferative Disorders Disease |
Immune System Diseases Hematologic Diseases Myelodysplastic Syndromes Leukemia, Myeloid Gemtuzumab Pharmacologic Actions Lymphatic Diseases Neoplasms Fludarabine Lymphoproliferative Disorders Leukemia, B-Cell Bone Marrow Diseases |